Hemostatic Agent Development

Period of Performance: 09/21/2010 - 07/26/2011


Phase 1 SBIR

Recipient Firm

Hybrid Plastics
55 W. L. Runnels Industrial Dr.
Hattiesburg, MS 39401
Principal Investigator


The proposed effort comprises a treatment combination using the platelet binding hemostatic capability of Nanoscopic Chemicals known as POSS trisilanols in combination with hyaluronic acid media, and antibiotic drugs in liquid and foam form. Mechanistically, liquid POSS trisilanols are injectable and serve to bind platelets to immediately stop bleeding. Subsequently the bound plateles release a multitude of natural growth factors while in the presence of a supplement of Hyaluronic acid (HA). Growth factors in combination with high amounts of HA are known to aid tissue repair and preservation.